These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4822 related articles for article (PubMed ID: 26952546)

  • 1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
    Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
    Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
    Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
    Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
    Powles T; Durán I; van der Heijden MS; Loriot Y; Vogelzang NJ; De Giorgi U; Oudard S; Retz MM; Castellano D; Bamias A; Fléchon A; Gravis G; Hussain S; Takano T; Leng N; Kadel EE; Banchereau R; Hegde PS; Mariathasan S; Cui N; Shen X; Derleth CL; Green MC; Ravaud A
    Lancet; 2018 Feb; 391(10122):748-757. PubMed ID: 29268948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
    Balar AV; Galsky MD; Rosenberg JE; Powles T; Petrylak DP; Bellmunt J; Loriot Y; Necchi A; Hoffman-Censits J; Perez-Gracia JL; Dawson NA; van der Heijden MS; Dreicer R; Srinivas S; Retz MM; Joseph RW; Drakaki A; Vaishampayan UN; Sridhar SS; Quinn DI; Durán I; Shaffer DR; Eigl BJ; Grivas PD; Yu EY; Li S; Kadel EE; Boyd Z; Bourgon R; Hegde PS; Mariathasan S; Thåström A; Abidoye OO; Fine GD; Bajorin DF;
    Lancet; 2017 Jan; 389(10064):67-76. PubMed ID: 27939400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
    Rittmeyer A; Barlesi F; Waterkamp D; Park K; Ciardiello F; von Pawel J; Gadgeel SM; Hida T; Kowalski DM; Dols MC; Cortinovis DL; Leach J; Polikoff J; Barrios C; Kabbinavar F; Frontera OA; De Marinis F; Turna H; Lee JS; Ballinger M; Kowanetz M; He P; Chen DS; Sandler A; Gandara DR;
    Lancet; 2017 Jan; 389(10066):255-265. PubMed ID: 27979383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
    Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
    Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
    Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
    Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
    Bellmunt J; Hussain M; Gschwend JE; Albers P; Oudard S; Castellano D; Daneshmand S; Nishiyama H; Majchrowicz M; Degaonkar V; Shi Y; Mariathasan S; Grivas P; Drakaki A; O'Donnell PH; Rosenberg JE; Geynisman DM; Petrylak DP; Hoffman-Censits J; Bedke J; Kalebasty AR; Zakharia Y; van der Heijden MS; Sternberg CN; Davarpanah NN; Powles T;
    Lancet Oncol; 2021 Apr; 22(4):525-537. PubMed ID: 33721560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
    Sharma P; Retz M; Siefker-Radtke A; Baron A; Necchi A; Bedke J; Plimack ER; Vaena D; Grimm MO; Bracarda S; Arranz JÁ; Pal S; Ohyama C; Saci A; Qu X; Lambert A; Krishnan S; Azrilevich A; Galsky MD
    Lancet Oncol; 2017 Mar; 18(3):312-322. PubMed ID: 28131785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
    Galsky MD; Arija JÁA; Bamias A; Davis ID; De Santis M; Kikuchi E; Garcia-Del-Muro X; De Giorgi U; Mencinger M; Izumi K; Panni S; Gumus M; Özgüroğlu M; Kalebasty AR; Park SH; Alekseev B; Schutz FA; Li JR; Ye D; Vogelzang NJ; Bernhard S; Tayama D; Mariathasan S; Mecke A; Thåström A; Grande E;
    Lancet; 2020 May; 395(10236):1547-1557. PubMed ID: 32416780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
    Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
    Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
    Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
    Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
    Bamias A; Davis ID; Galsky MD; Arranz JÁ; Kikuchi E; Grande E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; Panni S; Gumus M; Özgüroğlu M; Mariathasan S; Poloz Y; Bene-Tchaleu F; Lee C; Bernhard S; De Santis M
    Lancet Oncol; 2024 Jan; 25(1):46-61. PubMed ID: 38101431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
    Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
    Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
    Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
    Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
    Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
    Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
    Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
    Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 242.